• 1.

    United States Pharmacopeial Convention (USP). Compounding Compendium. Rockville, MD: USP; 2020.

  • 2.

    United States Pharmacopeial Convention (USP). USP general chapter <795> pharmaceutical compounding—nonsterile preparations. In: USP 43−NF 38 as of June 1, 2020. Rockville, MD: USP; 2020.

    • Search Google Scholar
    • Export Citation
  • 3.

    United States Pharmacopeial Convention (USP). USP general chapter <797> pharmaceutical compounding—sterile preparations. In: USP 43−NF 38 as of June 1, 2020. Rockville, MD: USP; 2020.

    • Search Google Scholar
    • Export Citation
  • 4.

    United States Pharmacopeial Convention (USP). USP general chapter <800> hazardous drugs—handling in healthcare settings. In: USP 43−NF 38 as of June 1, 2020. Rockville, MD: USP; 2020.

    • Search Google Scholar
    • Export Citation
  • 5.

    United States Pharmacopeial Convention (USP). USP general chapter <825> radiopharmaceuticals—preparation, compounding, dispensing, and repackaging. In: USP 43−NF 38 as of June 1, 2020. Rockville, MD: USP; 2020.

    • Search Google Scholar
    • Export Citation
  • 6.

    United States Pharmacopeial Convention (USP). USP general chapter <797> pharmaceutical compounding—sterile preparations. In: USP 42−NF 37. Second Supplement. Rockville, MD: USP; 2019.

    • Search Google Scholar
    • Export Citation
  • 7.

    Newton DW. United States Pharmacopeia chapter <797> timeline 1989 to 2013. Int J Pharm Compd. 2013; 17:283-8.

  • 8.

    US Food and Drug Administration. Repackaging of certain human drug products by pharmacies and outsourcing facilities, 2017. www.fda.gov/downloads/Drugs/Guidances/UCM434174.pdf (accessed 2020 May 22).

    • Search Google Scholar
    • Export Citation
  • 9.

    Kienle PC. The Chapter <800> Answer Book. Bethesda, MD: ASHP, 2017.

  • 10.

    United States Pharmacopeial Convention (USP). USP general chapter <1168> compounding for phase 1 investigational studies. In: USP 43−NF 38 as of June 1, 2020. Rockville, MD: USP; 2020.

    • Search Google Scholar
    • Export Citation
  • 11.

    US Food and Drug Administration. Compounded drug products that are essentially copies of a commercially available drug product under section 503a of the Federal Food, Drug, and Cosmetic Act, 2018. www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM510154.pdf (accessed 2020 May 22).

    • Search Google Scholar
    • Export Citation
  • 12.

    American Society of Health-System Pharmacists. ASHP sterile products preparation certificate program, 2019. www.ashp.org (accessed 2020 May 22).

    • Search Google Scholar
    • Export Citation
  • 13.

    CriticalPoint, LLC. Website. www.criticalpoint.info (accessed 2020 May 22).

  • 14.

    Board of Pharmacy Specialties. BPS board certified sterile compounding pharmacist (BCSCP). www.bpsweb.org (accessed 2020 May 22).

  • 15.

    Pharmacy Technician Certification Board. Certified compounded sterile preparation technician™ program. www.ptcb.org/about-ptcb/news-room/whats-new-at-ptcb/2017/12/06/ptcb-launches-certified-compounded-sterile-preparation-technician-(cspt-)-program (accessed 2020 May 22).

  • 16.

    Murdaugh LB. Competence Assessment Tools for Health-System Pharmacies. 5th ed. Bethesda, MD: American Society of Health-System Pharmacists; 2015.

    • Search Google Scholar
    • Export Citation
  • 17.

    American Society of Health-System Pharmacists (ASHP). ASHP’s Pharmacy Competency Assessment Center. Bethesda, MD: ASHP; 2019.

  • 18.

    United States Department of Labor, Occupational Safety and Health Administration. Hazard communication. www.osha.gov/dsg/hazcom/HCSFinalRegTxt.html (accessed 2020 May 22).

  • 19.

    Centers for Disease and Control Prevention. NIOSH list of antineoplastic and other hazardous drugs in healthcare settings, 2016. Publication number 2016-161. www.cdc.gov/niosh/docs/2016-161/pdfs/2016-161.pdf (accessed 2020 May 22).

    • Search Google Scholar
    • Export Citation
  • 20.

    United States Department of Labor, Occupational Safety and Health Administration. Hazard communication: small entity compliance guide for employers that use hazardous chemicals. www.osha.gov/Publications/OSHA3695.pdf (accessed 2020 May 22).

  • 21.

    Centers for Disease Control and Prevention. Hand hygiene in healthcare settings. www.cdc.gov/handhygiene (accessed 2020 May 22).

  • 22.

    ASTM International. ASTM D6978 standard practice for assessment of resistance of medical gloves to permeation by chemotherapy drugs. www.astm.org/Standards/D6978.htm (accessed 2020 May 22).

  • 23.

    ASTM F739-12e1. Standard Test Method for Permeation of Liquids and Gases through Protective Clothing Materials under Conditions of Continuous Contact. West Conshohocken, PA: ASTM International.

  • 24.

    Centers for Disease Control and Prevention, National Institute for Occupational Safety and Health. The national personal protective technology laboratory, respirator trusted-source information. www.cdc.gov/niosh/npptl/topics/respirators/disp_part/respsource.html (accessed 2020 May 22).

  • 25.

    Centers for Disease Control and Prevention. Safe injection practices to prevent transmission of infections to patients. www.cdc.gov/injectionsafety/ip07_standardprecaution.html (accessed 2020 May 22).

  • 26.

    Association for Professionals in Infection Control and Epidemiology. APIC position paper: safe injection, infusion, and medication vial practices in health care (2016). www.apic.org/Resource_/TinyMceFileManager/Position_Statements/2016APICSIPPositionPaper.pdf (accessed 2020 May 22).

    • Search Google Scholar
    • Export Citation
  • 27.

    Buchanan C, Schneider P, Forrey R. Compounding Sterile Preparations. 4th ed. Bethesda, MD: American Society of Health-System Pharmacists; 2017.

    • Search Google Scholar
    • Export Citation
  • 28.

    United States Pharmacopeial Convention (USP) general chapter <71> sterility tests. In: USP 43−NF 38 as of June 1, 2020. Rockville, MD: USP; 2020.

    • Search Google Scholar
    • Export Citation
  • 29.

    US Food and Drug Administration. FD&C Act provisions that apply to human drug compounding. www.fda.gov/Drugs/GuidanceComplianceRegulatoryInformation/PharmacyCompounding/ucm606955.htm (accessed 2020 May 22).

  • 30.

    United States Pharmacopeial Convention (USP). USP general chapter <1231> water for pharmaceutical purposes. In: USP 43−NF 38 as of June 1, 2020. Rockville, MD: USP; 2020.

    • Search Google Scholar
    • Export Citation
  • 31.

    Controlled Environment Testing Association. CETA application guides. www.cetainternational.org (accessed 2020 May 22).

  • 32.

    Institute for Safe Medication Practices. Guidelines for safe preparation of compounded sterile preparations. www.ismp.org/guidelines/sterile-compounding (accessed 2020 May 22).

  • 33.

    United States Pharmacopeial Convention (USP). USP general chapter <659> packaging and storage requirements. In: USP 43−NF 38 as of June 1, 2020. Rockville, MD: USP; 2020.

    • Search Google Scholar
    • Export Citation
  • 34.

    Rhoads R, Exner L, Wagner JT. Demystifying dynamic smoke pattern tests for sterile compounding pharmacies. Am J Health-Syst Pharm. 2020;77:56-60.

    • Search Google Scholar
    • Export Citation
  • 35.

    US Food and Drug Administration. Bulk drug substances used in compounding under section 503a of the FD&C Act. www.fda.gov/Drugs/GuidanceComplianceRegulatoryInformation/PharmacyCompounding/ucm614204.htm (accessed 2020 May 22).

  • 36.

    US Food and Drug Administration. Regulatory policy information. www.fda.gov/drugs/human-drug-compounding/regulatory-policy-information (accessed 2020 May 22).

  • 37.

    United States Pharmacopeial Convention (USP). USP general chapter <1178> good repackaging practices. In: USP 43−NF 38 as of June 1, 2020. Rockville, MD: USP; 2020.

    • Search Google Scholar
    • Export Citation
  • 38.

    American Society of Health-System Pharmacists. ASHP guidelines on compounding sterile preparations. Am J Health-Syst Pharm. 2014; 71:145-66.

    • Search Google Scholar
    • Export Citation
  • 39.

    Power LA, Coyne JW. ASHP guidelines on handling hazardous drugs. Am J Health-Syst Pharm. 2018; 75:1996-2031.

  • 40.

    Centers for Disease Control and Prevention. Biosafety in microbiological and biomedical laboratories (BMBL). 5th ed. www.cdc.gov/labs/BMBL.html (accessed 2020 May 22).

  • 41.

    International Journal of Pharmaceutical Compounding. Website. www.ijpc.com (accessed 2020 May 22).

  • 42.

    Centers for Disease Control and Prevention. Guidelines for the prevention of intravascular catheter-related infections. www.cdc.gov/mmwr/preview/mmwrhtml/mm5132a9.htm (accessed 2020 May 22).

  • 43.

    American Society of Health-System Pharmacists (ASHP). Handbook on Injectable Drugs. 20th ed. Bethesda, MD: ASHP; 2018.

  • 44.

    Dellamorte Bing C, Nowobilski-Vasilios A. Extended Stability for Parenteral Drugs. 6th ed. Bethesda, MD: American Society of Health-System Pharmacists; 2017.

    • Search Google Scholar
    • Export Citation
  • 45.

    King Guide Publications, Inc. King Guide to Parenteral Admixtures. Napa, CA: King Guide Publications; 2019.

  • 46.

    US Food and Drug Administration. MedWatch: the FDA safety information and adverse event reporting program. www.fda.gov/safety/medwatch-fda-safety-information-and-adverse-event-reporting-program (accessed 2020 May 22).

  • 47.

    United States Pharmacopeial Convention (USP). USP general chapter <1113> microbial characterization, identification, and strain typing. In: USP 43−NF 38 as of June 1, 2020. Rockville, MD: USP; 2020.

    • Search Google Scholar
    • Export Citation
  • 48.

    United States Pharmacopeial Convention (USP). USP general chapter <1163> quality assurance in pharmaceutical compounding. In: USP 43−NF 38 as of June 1, 2020. Rockville, MD: USP; 2020.

    • Search Google Scholar
    • Export Citation
  • 49.

    US Food and Drug Administration. Insanitary conditions at compounding facilities. www.fda.gov/media/124948/download (accessed 2020 May 22).

  • 1.1 Where can I find the full text of <797>?
  •    United States Pharmacopeial Convention (USP) publishes the USP Compounding Compendium.1 It contains all the major compounding chapters: USP General Chapter <795> Pharmaceutical Compounding—Nonsterile Preparations,2 USP General Chapter <797> Pharmaceutical Compounding—Sterile Preparations,3 USP General Chapter <800> Hazardous Drugs—Handling in Healthcare Settings,4 and USP General Chapter <825> Radiopharmaceuticals—Preparation, Compounding, Dispensing, and Repackaging5 as well as all the other chapters that are referenced in those core compounding chapters. Additionally, the General Notices that apply to compounding and compounding monographs are included. The USP Compounding Compendium is available through USP at www.usp.org as an annual subscription.
  •    Your subscription allows you to download updates throughout your subscription year. Be sure to do that each February, June, and November so you have the most current versions of existing chapters and any new General Notices, General Chapters, or monographs that were completed in the prior months.
  • 1.2 When did <797> become official?
  •    <797> has been an official standard since 2004. It was revised in 2008. A proposed revision was published in 2019 but was appealed and returned to the USP Compounding Expert Committee to evaluate and/or revise.6
  • 1.3 Why is there a need for a chapter on sterile compounding? Is this all about the meningitis scare from 2012?
  •    This is a focus on patient safety. It was first published in 2004, so <797> predates the meningitis tragedy of 2012. There were several issues of improper quality (strength as well as microbial contamination) that occurred in 1989 and 1990, prompting both a Food and Drug Administration (FDA) Alert and an ASHP Urgent Attention letter directed to sterile compounders.7 Those events and others led to the development of <797>.
  • 1.4 Is <797> a guideline? A requirement?
  •    <797> is a minimum standard. Regulators such as federal or state entities can make it a regulation by including it in their documents. Accreditation organizations, such as The Joint Commission, DNV-GL Healthcare, the Pharmacy Compounding Accreditation Boards, and others, can include it in their own standards.
  • 1.5 How can <797> be a minimum standard if my state hasn’t incorporated it into regulations?
  •    USP is a standard-setting organization. Even if your state has not codified it into regulation, it is still a federal standard and can be used to inspect or survey your pharmacy.

If the inline PDF is not rendering correctly, you can download the PDF file here.